Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Olumiant® (baricitinib): Lung Disease in the Rheumatoid Arthritis Clinical Development Program
Interstitial lung disease and pulmonary fibrosis with baricitinib treatment has been reported in the rheumatoid arthritis clinical development program.
UK_cFAQ_BAR148A_LUNG_DISEASE_RA
en-GB
Incidence of Interstitial Lung Disease in Rheumatoid Arthritis
Depending on the study population, the prevalence of clinically significant ILD among RA patients has been reported to range between 5% to 30% or higher.1-3
Interstitial lung disease is a relatively common extra-articular manifestation of RA with subclinical interstitial lung abnormalities detected in 30% to 50% of RA patients.1,2
In addition to being a relatively common complication of RA, ILD confers a higher risk of mortality.2-4
Interstitial Lung Disease and Pulmonary Fibrosis in the Rheumatoid Arthritis Clinical Development Program
Description of the All BARI RA Dataset
The All BARI RA analysis set included 3770 patients with RA who received BARI at a variety of doses from 1 phase 1, 3 phase 2, and 5 phase 3 studies (RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE). Data includes a long-term extension study (RA-BEYOND) with
Incidence of Interstitial Lung Disease in the All BARI RA Dataset
In the All BARI RA dataset, the MedDRA PT, ILD, was reported as a TEAE in 17 patients treated with BARI (0.5%; 0.1 EAIR); an EAIR of 0.1 per 100 PYE for patients treated with BARI is consistent with the background rate of ILD in patients with RA.7
Interstitial Lung Disease Events Leading to Temporary Interruption, Permanent Discontinuation, or Considered Serious
Of the 17 reported TEAEs of ILD, 13 patients had events that led to temporary interruption, permanent discontinuation, or were classified as SAE (see Incidence of Interstitial Lung Disease in the All BARI RA Safety Dataset).7
|
TEAE |
Treatment Interruption |
Permanent Study Discontinuation |
SAE |
All BARI RA (N=3770) |
17 (0.1) |
1 (0.0) |
9 (0.1) |
6 (0.05) |
Abbreviations: BARI = baricitinib; EAIR = exposure-adjusted incidence rate; RA = rheumatoid arthritis; SAE = serious adverse event; TEAE = treatment emergent adverse event.
Exposure-adjusted incidence rates were calculated as the number of patients with an event per 100 patient-years of exposure time, with exposure not censored at time of event.
Past Medical History
Three patients had a past medical history of ILD. One patient experienced an event >100 days after starting BARI.7
Confounding Variables
Ten patients were taking methotrexate concomitantly. Additionally, 2 of the patients reported smoking cigarettes.7
Resolution of Event
For the 7 patients who were hospitalized for ILD the event was considered resolved after hospitalization. Five patients were treated with antibiotics for pneumonia based on imaging or presentation with fever. Three patients had worsening cases, which resolved after antibiotics or hospitalization.7
Three patients that reported ILD adverse events died after hospitalization due to
- ILD
- acute respiratory failure, and
- lung infection.7
Incidence of Pulmonary Fibrosis in the All BARI RA Dataset
In the All BARI RA dataset, the MedDRA PT, pulmonary fibrosis, was reported as a TEAE in 5 patients treated with BARI (0.1%; 0 EAIR). None of these events was considered a SAE, and none of these events led to temporary or permanent discontinuation of study drug.7
Information from the Label
Interstitial lung disease is not listed among the adverse events listed in the summary of product characteristics.8
References
1Brito Y, Glassberg MK, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease: current concepts. Curr Rheumatol Rep. 2017;19(12):79. https://dx.doi.org/10.1007/s11926-017-0701-5
2Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700-1706. https://dx.doi.org/10.1136/annrheumdis-2017-211138
3Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-1591. https://dx.doi.org/10.1002/art.27405
4Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(3):344-350. https://dx.doi.org/10.1093/rheumatology/kew391
5Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Ann Rheum Dis. 2020;79(suppl 1):638. European League Against Rheumatism abstract FRI0123. https://ard.bmj.com/content/79/Suppl_1/642.1
6Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Poster presented at: European League Against Rheumatism Virtual Congress; June 3-6, 2020.
7Data on file, Eli Lilly and Company and/or one of its subsidiaries.
8Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
BARI = baricitinib
EAIR = exposure-adjusted incidence rate
ILD = interstitial lung disease
MedDRA = Medical Dictionary for Regulatory Activities
PT = preferred term
PYE = patient-years of exposure
RA = rheumatoid arthritis
SAE = serious adverse event
TEAE = treatment-emergent adverse event
Date of Last Review: 20 July 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays